NS Support & resources
833-NSSUPRT (833-677-8778)
Monday–Friday,
8 AM-8 PM
ET
At NS Support we are dedicated to being a committed partner to the families coping with Duchenne muscular dystrophy (DMD). We stand ready to provide optimal access support and resources—every step of the way—for patients, their caregivers, and healthcare professionals.
Support for physicians and their practices:
Patient Start Form Buy & Bill Order Form Patient Assistance Program Application Stay informed—sign up to receive additional information and updates >Support for patients and their caregivers:
Patient Authorization Form Patient Assistance Program Application Stay informed—sign up to receive additional information and updates >*Program covers the cost of the medication only and does not cover the costs to administer the infusion. See full Eligibility Requirements & Terms and Conditions on back of Affordability Options brochure.
Summarizes the clinical evidence of the efficacy and safety of VILTEPSO and other product features
Provides you with information on how to prescribe, dose, and administer VILTEPSO as infusion therapy
Provides information on initiating therapy and helping patients afford their treatment
Provides information on how to appropriately dose and deliver VILTEPSO. It also contains a representative dosing chart as a guide for weekly infusions
Explains the features of VILTEPSO in treating DMD, including efficacy and safety
Answers common questions about what VILTEPSO does, how it works, and other concerns you may have
Helps you better understand the weekly infusion process and address questions with your child in advance of their first session
Provides an overview of the NS Support Co-Pay Assistance program, Patient Assistance Program (PAP) and Medicaid waiver programs
Provides information about government-funded health insurance and financial assistance
Includes a list of foundations and advocacy groups that may be able to provide assistance to DMD patients
VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For more information about VILTEPSO, see full Prescribing Information.
For more information about VILTEPSO, see full Prescribing Information.